Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT07443202
Enrolling by invitation Phase 2

Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)

NCT07443202 · tracked via the Priya Life Science USA tracker
Sponsor
Tarsus Pharmaceuticals, Inc
Phase
Phase 2
Started
2025-12-05
Last updated
2026-03-02

Condition(s) studied

Ocular Rosacea

Investigational drug(s) / intervention(s)

lotilanerVehicle

lotilaner: lotilaner

Vehicle: Vehicle of lotilaner

Study summary

To evaluate lotilaner treatment in patients with ocular rosacea.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * 18 years of age or older at the time of consent. * Has moderate to severe ocular rosacea * Use of acceptable methods of contraception * Are willing to sign the informed consent form and is deemed capable of complying with the requirements of the study protocol Exclusion Criteria: * Patient taking a topical or other therapy which may affect the patients rosacea * Actively managed glaucoma or active ocular infection or ocular systemic disease * Have hypersensitivity to lotilaner or any of the formulation components * Are currently enrolled in an investigational drug or device study * Are currently pregnant or lactating or planning to become pregnant during the study

Primary outcome measure(s)

  • Incidence of Treatment Emergent Adverse Events — Week 16
    Number of patients with treatment related emergent adverse events (TEAEs)

Trial sites (2)

FacilityCityRegionStatus
Site Houston Texas
Site Lynchburg Virginia

More Tarsus Pharmaceuticals, Inc. trials in the USA

A Study to Evaluate the Efficacy and Safety of TP-06 for PCED Recruiting
A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07443202 on ClinicalTrials.gov ↗ ← All trials in the USA